The detection of cirrhosis is important in liver cancer management since it limits the spectrum of possible therapeutic strategies [22,52]; nonetheless, small-sized lesions may be missed where there is a high FAPI background uptake in cirrhotic patients [39,65,67]; we should also consider that small-sized lesions may show an absolutely lower uptake than larger-sized ones (lower hypoxia, which translates into lower FAP expression in CAFs) [67]. The gene discussed is FAP; the disease is Cirrhosis.